Category: Health

Covid-19 vaccine hesitancy among ethnic minority groups

In an editorial published in the British Medical Journal, we discuss the highly topical issue of Covid-19 vaccine hesitancy among ethnic minority groups. With mass Covid-19 vaccination efforts under way in many countries, including the UK, we need to understand and redress the disparities in its uptake. Data to 14 February 2021 show that over 90% of adults in Britain have received or would be likely to accept the covid-19 vaccine if offered. However, surveys have indicated much greater vaccine hesitancy among people from some ethnic minorities. In a UK survey in December 2020, vaccine hesitancy was highest among black, Bangladeshi, and Pakistani groups compared with people from a white ethnic background.

The legitimate concerns and information needs of ethnic minority communities must not be ignored, or worse still, labelled as “irrational” or “conspiracy theories.” We need to engage, listen with respect, communicate effectively, and offer practical support to those who have yet to make up their minds about the vaccine. Covid-19 vaccination is one of the most important public health programmes in the history of the NHS. Tackling vaccine hesitancy and ensuring that vaccination coverage is high enough to lead to herd immunity are essential for its success.

DOI: https://doi.org/10.1136/bmj.n513

Can the UK meet the government’s target of offering all adults a covid-19 vaccine by 31 July?

The Prime Minister Boris Johnson has set a target of offering a first dose of a covid-19 vaccine to all adults in the UK by the end of July 2021. What do we need to do to achieve this target? The first step is to ensure we have enough vaccines to offer first and second doses to all adults. There are around 53 million people aged 18 and over in the UK. If everyone took up the offer of a vaccination, we would require about 106 million vaccine doses, along with a small amount of vaccine for people under 18 who are classed as clinically extremely vulnerable.

Currently, we are using two vaccines in the UK: from AstraZeneca and Pfizer-BioNTech. A third vaccine from Moderna has been licensed in the UK but is not yet in use. Other vaccines—such as the candidate from Novavax—are in the late stages of development and approval; and may come into use in the UK by the early summer. The government will need to ensure that these companies can supply enough vaccines for use in the UK to meet its target date of 31 July.

How quickly do we need to vaccinate the UK population to meet the target? By 20 February, the UK had administered around 18 million doses of covid-19 vaccines (17.2 million first doses and 0.6 million second doses). This means that we need to administer around a maximum of another 88 million doses of vaccines if all adults in the UK accepted the offer of a vaccination and received two doses of vaccine.

In recent weeks, about 2.9 million doses of vaccine have been administered each week in the UK. As there are around 23 weeks until 31 July, we would be able to administer about a further 66 million vaccine doses by the target date, bringing the total doses administered to 84 million. This would be sufficient to provide all 53 million adults in the UK with at least one dose and also to provide 31 million of these people with two doses of vaccine.

Maintaining the same pace of vaccination after July would allow all adults in the UK to receive two doses of vaccine by mid to late September. In practice, we may need less than a total of 106 million doses of vaccine to immunise adults in the UK because not everyone will take up the offer of a covid-19 vaccination. Hence, the target of “offering” all adults in the UK a first dose vaccine by 31 July looks achievable if the supply and administration of vaccines can both be maintained at their current rates.

It’s also worth considering whether the UK should be more ambitious in its target. For example, if there was sufficient capacity in the NHS to offer 3.8 million doses of vaccine per week —an increase of 31% on the current vaccination rate—and vaccine supplies to allow this, all adults in the UK could receive two doses of vaccine by 31 July. In either scenario, 2.9 million doses weekly or 3.8 million doses weekly, the UK would have offered two doses of vaccine to all adults in the UK before the Autumn and thus would be better prepared for any seasonal increase in covid-19 infections than it was in 2020.

Maintaining an average of 2.9 million vaccinations per week for the next 23 weeks is ambitious, but it looks practical if vaccination sites can be guaranteed sufficient doses of vaccine.  Vaccination sites will also need to have deliveries timetabled well in advance so that clinics can be planned and patients booked in for appointments. It’s therefore critical that we avoid the problems seen in the earlier phase of the vaccination programme, when deliveries of vaccines to vaccination sites were often arriving late or being cancelled at short notice. This created logistical and planning difficulties for vaccination teams, as well as being very inconvenient for patients who had their appointments cancelled.

We also need to bear in mind that we have thus far been vaccinating groups of people, such as older or clinically vulnerable people and frontline healthcare professionals, where vaccine uptake has been very high. As we start to vaccinate younger, healthier groups of people, we may find vaccine uptake is lower than in older people because of greater levels of vaccine hesitancy. We need to ensure that we engage with vaccine hesitant groups—whether these are younger people or people from ethnic minority communities—to achieve a very high uptake of covid-19 vaccination. Broad population coverage is the vaccination programme’s best hope of success in helping to limit the spread of covid-19, allowing the UK to gradually relax its covid-19 control measures.

At this point, we also don’t yet know if booster vaccines will be required later in the year or in 2022 to deal with the effects of any decline in immunity following vaccination, or to provide protection against new variants of SARS-CoV-2 if older vaccines are less effective. If this is the case, we will need to put in place the infrastructure to deliver additional doses of vaccines to all adults in the UK, making the covid-19 vaccination programme like the influenza one but on a much bigger scale. It’s also possible that we will have vaccines licensed for use in children later this year, which will further increase the number of people who need to be vaccinated. The size of the covid-19 vaccination programme and its importance in allowing a return to a more normal way of life in the UK means that it must be meticulously planned and adequately funded for the indefinite future.

In conclusion, the government’s vaccination target looks achievable if it can guarantee sufficient supplies of vaccine; improve the planning of deliveries to vaccination sites; and provide vaccination teams with the required financial, administrative, and personnel support. This needs to be done at the same time as the NHS deals with all its other emergency and elective work, as well as with the large backlog of work caused by covid-19. As the majority of covid-19 vaccines have been delivered by primary care teams, particular emphasis must be placed on supporting NHS primary care during this period to ensure successful achievement of the vaccination target.

This article was first published in BMJ Opinion.

How can we address Covid-19 vaccine hesitancy and improve vaccine acceptance?

Vaccination offers the UK the best exit strategy from the covid-19 pandemic. [1] To accomplish this objective, achieving high population coverage of covid-19 vaccination is essential. However, despite the good safety and efficacy of covid-19 vaccines, public scepticism about the vaccines persists. [2] Vaccine opposition has existed for as long as vaccinations and, despite the public’s increasing scientific sophistication, has been growing across high-income countries, leading the WHO to list it in the top 10 global health threats in 2019. [3,4] In the UK, the covid-19 vaccination programme continues to gather pace, giving the UK a rare pandemic win; however, those prioritised for vaccination represent groups with low vaccine hesitancy rates. There have been many surveys assessing covid-19 vaccine hesitancy. Potentially affecting as many as one in three individuals in the UK, vaccine hesitancy is pervasive, especially amongst young adults and ethnic minorities, threatening to undermine the pandemic response. [5-7] To avoid disrupting the vaccination programme’s success, developing strategies that address vaccine scepticism is essential.

To dispel vaccine misinformation and myths, differentiating between the under-vaccinated, the anti-vaxxers, and the vaccine-hesitant is required. The vaccine-hesitant represent those who are uncertain about getting vaccinated, but remain open to it if they are convinced that vaccines are safe, effective, and necessary. In the vaccine-hesitant, it is essential to differentiate between vaccine-associated misinformation and mistrust.

A recent survey carried out by the Royal College of General Practitioners demonstrated that people of Black, Asian and mixed ethnic backgrounds are 53%, 36% and 67% less likely to have been vaccinated when compared to their white counterparts. [8] In the US, 32% of Black adults would definitely, or probably, get vaccinated if made available at no expense, compared to 52% of White adults. [9] While these communities are not ill-informed regarding their heightened risk of severe illness and death from covid-19, hesitancy in ethnic minorities remains disproportionately high. [9] Mistrust felt by this population is not irrational and must be addressed with respect. In addition to a history of systemic racism, which affects many Black people globally, the pandemic has allowed mistrust of covid-19 vaccines to thrive; as stated by the WHO, “racist remarks”, including French doctors suggesting Africa should be a testing ground for coronavirus, are not helpful and this “colonial mentality has to stop.” [10] In the UK, 90.6% of covid-19 vaccine recipients are white. [8] To avoid increasing the health inequalities that covid-19 has harshly exposed, engaging with vaccine-hesitant subgroups is required to increase knowledge levels, reduce perceived risks, and enable informed decision-making. Enhancing vaccine access and convenience will also improve support for vaccination. [11]

As real-time evidence continues to emerge, and mass vaccination campaigns approach vaccine-hesitant groups, culturally sensitive and tailored risk communication and messaging, co-involving faith and influential community leaders, are required to continuously inform, update, and reassure the public. [12] Covid-19 vaccines are unlikely to be made mandatory. Nudging individuals, through choice-offering strategies, incentivises vaccination, and aligns intention with actions. [13] Scientists proactively listening to concerns of subgroups and sharing risks and benefits in a manner that does not impose, but persuades, will improve voluntary cooperation. [13] As there are genuine concerns regarding their record-breaking timescales, alleviating uncertainties about vaccine safety and efficacy is essential. Communicating carefully that their development has followed the same legal requirements for pharmaceutical quality, safety, and efficacy as other medicines, and circulating accurate information including how advances in Ebola, whooping cough, rabies, human papillomavirus and hepatitis A and B vaccine technologies were leveraged for covid-19 vaccine development is important. [14,15]

The availability of online anti-vaccine narratives represents the leading cause of the rise in vaccine hesitancy; accessing these platforms for five to ten minutes increases the perception of risk of vaccines and reduces the perception of risk of refusing vaccines and intention to vaccinate. [16,17] While a number of the “next generation” covid-19 vaccines are based on sequence information, as opposed to “classical” virus- or protein-based vaccines, these vaccines are built on years of developments in infrastructure, knowledge and technical capacity. [18] Removing seeds of doubt requires filling information voids through carefully-designed health surveys, observational qualitative research and social media listening that avoid information overload and the unintentional generation of misinformation through, for example, multiple-choice questions that can lead respondents to misremember false responses as correct. [19,20] Additionally, addressing science-based uncertainty and reduced confidence in public health requires clear communication about the science and building trust through community outreach, respectively. [19]

Drugs, including vaccines in vials, remain useless unless people take them. The WHO’s 10-year Blue Nile Health Project, in Sudan, demonstrated limited success of mass drug administration and confirmed that a holistic and sustainable approach, inclusive of political commitment, community engagement and socioeconomic development, are all required for disease control. [21] The 2009-2010 H1N1 pandemic also demonstrated that vaccine communication efforts were a big challenge and increasing public compliance and confidence in governments and medical facilities depend on coordinated efforts. [22-23]

Vaccines stand at the crossroad between an individual’s decision to accept an intervention and the public health benefits achieved when uptake is sufficiently high. At a time when unity is crucial, additional strategies are required to reach diverse communities, build civic awareness, develop a sense of collective purpose and, ultimately, arm the population with the information needed to defeat covid-19, the latest vaccine-preventable disease we face.

Tasnime Osama, Honorary Clinical Research Fellow, Department of Primary Care & Public Health, Imperial College London

Azeem Majeed, Professor of Primary Care & Public Health, Department of Primary Care & Public Health, Imperial College London

This article was first published by BMJ Opinion.

References

  1. Majeed A, Molokhia M. Vaccinating the UK against covid-19. BMJ. 2020; 371 :m4654. doi: https://doi.org/10.1136/bmj.m4654
  2. Markovitz G, Russo A. Survey Shows Rising Vaccine Hesitancy Threatening COVID-19 Recovery. World Economic Forum. 2020. https://www.weforum.org/press/2020/11/survey-shows-rising-vaccine-hesitancy-threatening-covid-19-recovery/
  3. Wolfe RM, Sharp LK. Anti-vaccinationists past and present. BMJ. 2002;325(7361):430-432. doi:10.1136/bmj.325.7361.430
  4. World Health Organization. Ten threats to global health in 2019. https://www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019
  5. Savage M. One in three ‘unlikely to take Covid vaccine’. The Guardian. 2020. https://www.theguardian.com/world/2020/dec/06/one-in-three-unlikely-to-take-covid-vaccine
  6. Office for National Statistics. Coronavirus (COVID-19) weekly insights: latest health indicators in England, 18 December 2020. 2020. https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/articles/coronaviruscovid19weeklyinsights/latesthealthindicatorsinengland18december2020#preventative-measures-and-vaccine-attitudes
  7. Scientific Advisory Group for Emergencies. Factors influencing COVID-19 vaccine uptake among minority ethnic groups. 2021. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/952716/s0979-factors-influencing-vaccine-uptake-minority-ethnic-groups.pdf
  8. Royal College of General Practitioners. GPs call for high-profile campaign backed by faith leaders and prominent figures from BAME communities to increase COVID-19 vaccine uptake. 2021. https://www.rcgp.org.uk/about-us/news/2021/february/gps-call-for-high-profile-campaign-backed-by-faith-leaders.aspx
  9. Tyson A, Johnson C, Funk C. U.S. Public Now Divided Over Whether To Get COVID-19 Vaccine. Pew Research Center. 2020. https://www.pewresearch.org/science/2020/09/17/u-s-public-now-divided-over-whether-to-get-covid-19-vaccine/
  10. World Health Organization. COVID-19 virtual press conference – 6 April, 2020. 2020. https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-06apr2020-final.pdf?sfvrsn=7753b813_2
  11. Thomson A, Robinson K, Vallée-Tourangeau G. The 5As: A practical taxonomy for the determinants of vaccine uptake. Vaccine. 2016;34(8):1018–24. doi: https://doi.org/10.1016/j.vaccine.2015.11.065
  12. UNICEF. Partnering with Religious Communities for Children. 2012. https://sites.unicef.org/about/partnerships/files/Partnering_with_Religious_Communities_for_Children_(UNICEF).pdf
  13. Dubov A, Phung C. Nudges or mandates? The ethics of mandatory flu vaccination. Vol. 33, Vaccine. 2015;33(22):2530–5. doi: 10.1016/j.vaccine.2015.03.048
  14. European Medicines Agency. COVID-19 vaccines: key facts. 2020. https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/covid-19-vaccines-key-facts
  15. Wellcome. What different types of Covid-19 vaccine are there? 2021. https://wellcome.org/news/what-different-types-covid-19-vaccine-are-there
  16. Vivion M, Hennequin C, Verger P, Dubé E. Supporting informed decision-making about vaccination: an analysis of two official websites. Public Health. 2020;178:112–9. doi: https://doi.org/10.1016/j.puhe.2019.09.007
  17. Betsch C, Renkewitz F, Betsch T, Ulshöfer C. The influence of vaccine-critical websites on perceiving vaccination risks. J Health Psychol. 2010;15(3):446–55. doi: 10.1177/1359105309353647
  18. van Riel D, de Wit E. Next-generation vaccine platforms for COVID-19. Nat. Mater. 2020;19: 810–12. doi: https://doi.org/10.1038/s41563-020-0746-0
  19. MacDonald NE, Dubé E, Greyston D D, Graham JE. Beware the public opinion survey’s contribution to misinformation and disinformation in the COVID-19 Pandemic. Canvax. 2020. https://canvax.ca/brief/beware-public-opinion-surveys-contribution-misinformation-and-disinformation-covid-19
  20. Roediger HL, Marsh EJ. The positive and negative consequences of multiple-choice testing [Internet]. Vol. 31, J Exp Psychol Learn Mem Cogn. 2005;31:1155–59. doi: https://doi.org/10.1037/0278-7393.31.5.1155
  21. Amin M, Abubaker H. Control of schistosomiasis in the gezira irrigation scheme, Sudan. J Biosoc Sci. 2017;49(1):83–98. doi: 10.1017/S0021932016000079
  22. Schnirring L. H1N1 LESSONS LEARNED Vaccination campaign weathered rough road, paid dividends. Center for Infectious Disease Research and Policy. 2010. https://www.cidrap.umn.edu/news-perspective/2010/04/h1n1-lessons-learned-vaccination-campaign-weathered-rough-road-paid
  23. Mesch GS, Schwirian KP. Social and political determinants of vaccine hesitancy: Lessons learned from the H1N1 pandemic of 2009-2010. Am J Infect Control. 2015;43(11):1161–65. doi: 10.1016/j.ajic.2015.06.031

When and how should we relax Covid-19 lockdown restrictions in the UK?

There is increasing discussion about how and when we should relax Covid-19 lockdown restrictions in the UK. My view is that we should be guided by data on case numbers, hospitalisations and deaths; and lift restrictions cautiously. In recent weeks, we have seen positive progress on case numbers with the daily number of people with positive Covid-10 tests falling from a peak over 50,000 per day earlier in the year to under 15,000 per day more recently. Hospitalisations and deaths are also falling but will lag behind the decrease in case numbers.

There are reasons to be positive about the future. Vaccination numbers are increasing daily with over 15M people now vaccinated against Covid-19, and administration of second vaccine doses due to start soon, as well as extension of vaccination to younger age groups. We are on target to offer a Covid-19 vaccine to all adults by later in 2021. However, we have seen lower vaccination rates in some groups, such as people from ethnic minorities, and it is essential to work with communities to overcome this vaccine hesitancy.

Another reason for optimism is that a large number of people also have some natural immunity to Covid-19 because of previous infection. Last year’s experience also shows that there is a seasonal effect on case numbers. Hence, we can be optimistic about seeing a decline in Covid-19 case numbers in the summer. We need though to avoid lifting restrictions too quickly and should do so in a gradual manner starting with opening up schools, and then opening up other sectors of the economy and society to avoid an increase in cases, hospitalisations and deaths in the Spring.

Finally, we need to be fully prepared for a potential increase in Covid-19 cases in the Autumn and Winter. This means ensuring that a high proportion of adults have had two doses of vaccine, and that we have a fully functional test and trace system in place by then. We are also likely to need continuing restrictions on overseas travel and travel to the UK; as well as planning for “booster” doses of vaccines to protect against newer and more infectious strains of SARS-CoV-2.

All-Party Parliamentary Group on Coronavirus

I was invited to join a meeting of the All-Party Parliamentary Group on Coronavirus earlier today when I was questioned on the implementation of the Covid-19 vaccination programme in the UK, vaccine hesitancy and how this can be addressed, and how we can ensure the programme is successfully completed.

The UK has made an excellent start to its Covid-19 vaccination programme and we should build on this success by supporting and investing in local primary care and pharmacy teams. The mass vaccination centres set up by NHS England may have a role but we must ensure that they do not divert staff, funding and vaccines from local vaccination centres run by primary care teams. Local centres can work flexibly and are more accessible for patients.

Finally, vaccine hesitancy is an important issue and we must work locally, as well as nationally, with the public and patients, to address this in the groups where it is highest – such as young adults, ethnic minorities, and people from poorer backgrounds.

Vdeo: https://www.pscp.tv/w/1BRKjBVaogvKw

Healthier schools during the COVID-19 pandemic: ventilation, testing and vaccination

In an article published in the Journal of the Royal Society of Medicine, we discuss how the UK can make its schools more Covid-secure. We were very grateful that Louise Voden, Head Teacher of the Nower Hill High School in Middlesex was able to contribute to the paper as a co-author.

Children are more likely than adults to have a mild or asymptomatic infection; hence, Covid-19 infection often goes undetected in children. When symptomatic, children shed the virus in similar quantities to adults and can infect others but it is unclear how infectious children with asymptomatic infections are. Large outbreaks of Covid-19 in schools have not been frequently reported but this may be because school outbreaks are rarely investigated in detail; for example, through the use of mass testing when after a case has been detected in a child, to determine the true infection rate among children in the school.

To keep schools open, there is an urgent need to implement more effective on-site mitigation strategies – with particular attention to ventilation and testing. In addition, it is essential that teachers and other school staff should be added to the priority list for vaccination. As far as ventilation is concerned, we suggest undertaking a feasibility study of implementing better ventilation and filtration systems in schools as well as some pilot work and research involving indoor air quality experts. Until then, keeping doors and windows open – for as much as is reasonably practicable – seems to be the best way forward.

Regarding Covid-19 tests, there is an urgent need to develop an appropriate guideline for schools on how staff and students should be tested regularly to work towards Covid-mitigated environment in schools. The recommendations on ventilation, testing and vaccination need to be combined with other infection control measures, such as wearing face masks or face coverings for staff and older students, regular cleaning of surfaces and frequent handwashing.

A failure to implement adequate control measures could result in Covid-19 outbreaks in schools then extending to the wider community, which would be a threat to public health, particularly for more vulnerable people such as the elderly, as well as leading to harm to children and families from school closures.

DOI: https://doi.org/10.1177/0141076821992449

COVID-19 Vaccination in the UK: We Need a Sustainable Infrastructure for the Programme

Earlier during the week starting on 15 February, we learned that more than 15 million people in the UK have now received their first dose of a COVID-19 vaccine, including more than 90% of people aged 75 and over. All residents of care homes have also now been offered a vaccination. This is excellent news and means that the groups that for the vast majority of COVID-19 deaths have now been immunised.

We will start to see the effects of vaccination in the coming weeks once enough time has elapsed for people to develop post-vaccination immunity. In particular, this should result in a reduced burden on the NHS as well as a lower death rate. But although we can be proud about what the vaccination achieved, we also need to remember that the programme is a marathon and not a sprint. There is a lot more work to do yet to complete the programme.

As well as continuing to offer first doses of vaccine to people, in April we will need to start offering the delayed second doses of vaccine, which will substantially increase the workload generated by the vaccination programme and place greater demands on NHS vaccination teams. We have also thus far been vaccinating the groups where “vaccine hesitancy” is generally low, such as the elderly and health professionals. As the figure below shows, from the UK Office for National Staistics, we will now start to vaccinate younger people, among whom vaccine hesitancy is at a much higher level than among older people.

Vaccine hestitancy is also more common in Black and other minority ethnic groups, as shown below, in a figure also from the UK Office for National Statistics. These groups are at higher risk of infection, severe disease and death. Hence, it is essential that vaccine hesitancy is also addressed in ethnic minority groups through sustained engagement with communities.

It’s also possible that people will need additional “booster” doses of vaccine at some point to counteract the effects of decreasing vaccine-generated immunity and to deal with new variants of SARS-CoV-2 amongst which current vaccines may be less effective. To help develop these modified vaccines, we will need continued research and it’s essential that members of the public sign up to take part in these projects; in particular, older people and people from ethnic minority groups, both of whom are often under-represented in trials.

We have made great progress in developing vaccines and implementing a vaccination programme. Congratulations to all for this; including industry, universities, government, the NHS and the public. But we are only at the start of this programme. We will need a sustainable, long-term vaccine infrastructure that will require investment and staffing, as well as continuing to update our vaccines to deal with new variants of SARS-CoV-2 if current vaccines are not fully effective against them.

THIS ARTICLE WAS UPDATED ON 17 FEBRUARY 2021: Over 15 million people in the UK have now received at least one dose of Covid-19 vaccine. The challenge will be to maintain this pace when we start giving second doses of vaccine to this group later in March, whilst also giving other target groups their first dose.

Your Covid-19 vaccine questions answered

My gran has had both her jabs. Once lockdown has ended, can I go and see her?

Once lockdown ends and the prohibition on people from different households mixing indoors stops, including for the clinically extremely vulnerable, you would be able to visit your grandmother. However, it may be some time before this happens.

I’ve been shielding on my own. Once I’ve had the vaccine will I be able to form a bubble with other family members?

You would need to continue to follow any lockdown rules that are in place in your local area even after you have had two doses of the vaccine.

I’ve had my first vaccine – can I hug my grandchildren?

One vaccination offers only partial protection. Two vaccinations are needed for maximum protection. Even after receiving two doses of vaccine, you would still need to follow any lockdown rules that were in place in your local area.

Can my employer force me to get vaccinated?

It’s unlikely that employers could force you to get vaccinated but they could recommend vaccination for staff who have public-facing roles that place them at increased risk of infection.

Everyone in my mum’s care home has had the vaccine. Should they allow relatives to visit without a screen?

Relatives will continue to need to be screened for now because the Covid-19 vaccines are not 100% effective even after two doses and some vaccinated people can still get infected. The risk of serious illness, complications and death is very high in people living in care homes and we have to be particularly cautious with this group.

Can I still be fined for breaking the rules if I show my vaccine card?

A vaccine card does not exempt you from following any local or national rules that are in place; so yes, you can be fined for breaking lockdown rules even if you have proof of vaccination.

Once everyone has been vaccinated, might there be places those who have refused the vaccine aren’t allowed?

It’s possible that some places might implement this policy. For example, some cruise companies have said they will require proof of vaccination from customers.

Will I need to show proof of my vaccine to travel abroad?

It’s possible that some countries will require proof of vaccination before allowing you to travel there but this will vary from country to country.

If I’ve had my vaccine will I still have to self-isolate if I’ve been in contact with someone who tested positive?

If you have been in recent contact with someone who has tested positive, you would still need to self-isolate for 10 days because at this point, we don’t know if vaccination stops you being infectious.

When will we know if the vaccine just stops you getting symptoms or stops you actually getting infected?

It will take some time for research to establish this. We may find out later in 2021.

If one of my employees has been vaccinated, should I consider him/her for a role that has a higher risk of infection?

Employers should risk assess staff before placing them in a specific role. My view is that vaccination should not be used as a reason for placing potentially clinically vulnerable staff in high-risk roles that expose them to a greater risk of infection.

I’m a piano teacher. Can I advertise for students using my proof of vaccination to show I’m Covid free?

Vaccination does not guarantee that you will be “Covid-free”. You would need to continue to follow any lockdown rules that are in place in your local area.

My Medical and Public Health Wish List for 2021

2020 was a difficult year for many people all over the world (if only we had the benefit 20-20 hindsight at the start of the year). Here is a list of 10 developments I would like to see in 2021.

1. A much better government response to the Covid-19 pandemic with interventions introduced at the right time and correct scale.
2. A rapid rollout of the Covid-19 vaccination programme so that target groups such as older people, those with long-term health problems, NHS staff and other key workers such as teachers and people working in high-risk occupations can be protected.
3. Awareness that the Covid-19 pandemic must be ended globally, not just in richer countries, and ensuring that people across the globe have access to the vaccines that will be introduced in 2021.
4. Better government policies to address key health challenges and risk factors for poor health such as poor diets, lack of exercise, and obesity; along with the wider determinants of health such as housing, education, poverty, and employment.
5. Greater support for our schools and teachers who have been outstanding in 2020 in trying to keep children educated during the midst of a global pandemic.
6. Respect for science and a reduction in the anti-science conspiracy theories that are some common on social media and in everyday conversations.
7. Greater support and recognition of the role played by primary care in ensuring good access to healthcare and improved health outcomes globally.
8. A positive relationship with our European neighbours and with the European Union.
9. An adequate replacement for the ERASMUS programme so that or students can benefit from the social, cultural and education opportunities that placements at universities in other European countries can bring.
10. An improvement in the IT systems that staff working in the NHS have to use. Poor IT leads to high levels of stress among NHS staff, and wastes valuable time and money that could be used to better effect elsewhere.

This is just a small list. Let me know what’s on your wish list for 2021.

Returning to physical activity after a Covid-19 infection

In an article published in the British Medical Journal, we discuss returning to physical activity after a Covid-19 infection. A risk-stratification approach can help maximise safety and mitigate risks, and several factors need to be taken into account. First, is the person physically ready to return to activity? In the natural course of Covid-19, deterioration signifying severe infection often occurs at around a week from symptom onset. Therefore, consensus agreement is that a return to exercise or sporting activity should only occur after an asymptomatic period of at least seven days, and it would be pragmatic to apply this to any strenuous physical activity. English and Scottish Institute of Sport guidance suggests that, before re-initiation of sport for athletes, activities of daily living should be easily achievable and the person able to walk 500 metres on the flat without feeling excessive fatigue or breathlessness. However, we recommend considering the person’s pre-illness baseline, and tailoring guidance accordingly.